Vofopitant NEW
| Price | $100 | $247 | $367 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-09 |
Product Details
| Product Name: Vofopitant | CAS No.: 168266-90-8 |
| Purity: 97.96% | Supply Ability: 10g |
| Release date: 2026/06/09 |
Product Introduction
Bioactivity
| Name | Vofopitant |
| Description | Vofopitant (GR 205171) is a potent NK1 receptor antagonist with anxiolytic and antiemetic activity for the study of post-traumatic stress disorder (PTSD). |
| In vitro | Co-administration of paroxetine (4 mg/kg; i.p.) with the NK1 receptor antagonists, Vofopitant/GR205171 (30 mg/kg; i.p.) or L733060 (40 mg/kg; i.p.), potentiated the effects of paroxetine on cortical [5-HT]ext in wild-type mice, whereas GR205171 (30 mg/kg; i.p.) had no effect on paroxetine-induced increase in cortical [5-HT]ext in NK1 receptor knock-out mice. When GR205171 (300 micro mol/L) was perfused by 'reverse microdialysis' into the dorsal raphe nucleus, it potentiated the effects of paroxetine on cortical [5-HT]ext, and inhibited paroxetine-induced increase in [5-HT]ext in the dorsal raphe nucleus[2]. |
| In vivo | In a T-maze experiment, Vofopitant (GR205171, 30 mg/kg, subcutaneously) enhances the selection of a 25-second delayed reward[3]. Furthermore, when administered intraperitoneally at the same dosage, Vofopitant elevates extracellular serotonin (5-HT) levels in the frontal cortex of wild-type mice treated with paroxetine, but not in untreated wild-type or in NK1 receptor knockout mice also treated with paroxetine[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Vofopitant | Rat NK1 receptor | NK1 | Neurokininreceptor | Neurokinin receptor | Human NK1 receptor | GR-205171 | GR205171 | Ferret NK1 receptor |
| Inhibitors Related | Maropitant citrate | Lanepitant 2HCl | Rolapitant | Ezlopitant | Octahydroisoindole | (R)-CJ 11974 | Netupitant | Aprepitant | Vofopitant dihydrochloride | Befetupitant | Fosaprepitant dimeglumine | Maropitant |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $100.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-09 | |
| $100.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY